Systematic review · people

PT-141: nausea in 40.0% vs 1.3% on placebo in phase 3 safety data

Checked against the paper Systematic reviewPublished by PepVault

The takeaway

Nausea is the side effect most likely to show up on bremelanotide and the main reason people quit; blood pressure bumps were small and brief, and the authors advise care for people at risk of heart disease.

Kind
Systematic review
Studied in
People
Number studied
3500
Published
2022
Journal
J Womens Health (Larchmt)

What they tested

The team set out to describe the side effects and safety of bremelanotide across its whole clinical program, from phase 1 through phase 3.

How the study was done

A review of safety data from 43 completed studies with 3500 people, including a pooled look at the double-blind, placebo-controlled part of the phase 3 studies in 1247 people. In phase 3, people used bremelanotide for up to 18 months.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking PT-141? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In the pooled phase 3 data, nausea was the most common side effect (40.0% on bremelanotide vs 1.3% on placebo, a dummy shot), followed by flushing (20.3% vs 1.3%), headache (11.3% vs 1.9%) and injection site reactions (5.4 vs 0.5). Nausea was the top reason people stopped the drug, and 70% of the bremelanotide group moved on to the open-label phase vs 87% of the placebo group. No one died, and a few people had serious side effects. Patches of darkened skin were rare at label dosing but showed up in more than one-third of people given up to 16 daily doses in a row, and blood pressure rose slightly for a short time during ambulatory monitoring, meaning readings taken as people went about their day.

What it doesn’t show

This is a safety review, so it does not show how well the drug works. The darkened skin result came from daily dosing outside the label schedule, and the long-term data reach only 18 months.

The paper

Clayton et al. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt). 2022.

The compound

More studies on PT-141

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking PT-141? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo